Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

98.44 +1.59 (+1.64%)
Streaming Delayed Price Updated: 3:42 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 636,292
Open 97.35
Bid (Size) 98.41 (300)
Ask (Size) 98.47 (500)
Prev. Close 96.85
Today's Range 97.15 - 99.40
52wk Range 81.20 - 129.27
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 
Via Stocktwits
Topics Supply Chain
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based... 
Via PredictStreet
Topics Initial Public Offering

Performance

YTD
+1.8%
+1.8%
1 Month
+1.2%
+1.2%
3 Month
-6.4%
-6.4%
6 Month
-10.5%
-10.5%
1 Year
-18.1%
-18.1%

More News

Read More
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Via Investor's Business Daily
Topics Death
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Via Benzinga
News headline image
BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗
Via Stocktwits
News headline image
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗
Via Benzinga
News headline image
BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss ↗
Via Chartmill
News headline image
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Host Innovation Series R&D Day on November 11, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
From BioNTech SE
Via GlobeNewswire
News headline image
Beyond The Numbers: 7 Analysts Discuss BioNTech Stock ↗
Via Benzinga

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 98.44
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 01/06/26 03:42 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.